RT Journal Article
SR Electronic
T1 A Divide and Conquer Strategy against the Covid-19 Pandemic?!
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20092155
DO 10.1101/2020.05.05.20092155
A1 Mangat, Patrick
YR 2020
UL http://medrxiv.org/content/early/2020/05/09/2020.05.05.20092155.abstract
AB The concern about (socio-)economic consequences of collective lockdowns in the Covid-19 pandemic calls for alternative strategies. We consider a divide and conquer strategy in which a high risk group (HRG) is put on strict isolation, whereas the remainder of the population is exposed to the virus, building up immunity against Covid-19. The question is whether this strategy may suppress the effective reproduction number below the critical value of without further lockdown once the HRG is released from isolation. While this proposal appears already rather academic, we show that can only be obtained provided that the HRG is less than ~ 20 − 30% of the total population. Hence, this strategy is likely to fail in countries with a HRG larger than the given upper bound. In addition, we argue that the maximum infection rate occurring in this strategy is likely to exceed realistic capacities of most health care systems. While the conclusion is rather negative in this regard, we emphasise that the strategy of stopping the curve at an early stage of the Covid-19 pandemic has a chance to work out. The required duration of the lockdown is estimated to be τ ~ 14 days/ (up to some order one factor) for , provided a systematic tracing strategy of new infections exists for the subsequent relaxation phase. In this context we also argue why remains the crucial parameter which needs to be accurately monitored and controlled.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis preprint has been written out of private interest in the topic of epidemiology. Hence, no funding is to be reported. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used are available via the links provided in the references. https://github.com/CSSEGISandData/COVID-19